Login
From:
Pulmonary Hypertension News
(Uncensored)
subscribe
Orphan Drug Designation Granted to Cereno Scientific’s CS1 for PAH
https://pulmonaryhypertensionnews.com/news/fda-grants-orphan-drug-designation-to-cereno-scientifics-lead-candidate-cs1-for-pah/
links
backlinks
Tagged with:
covid-19
fda
clinical trials
cs1
orphan drug
cereno scientific
hdac
The U.S. FDA has granted orphan drug designation to CS1, Cereno Scientific’s lead therapy candidate for treating pulmonary arterial hypertension (PAH).
Roast topics
Find topics
Find it!
